| 2014-CHMI-66831 | |
| Antimicrobial resistant microorganisms are those that have lost sensitivity to one or more antimicrobial drugs. The World Health Organization recognizes antimicrobial resistance as a current global threat that has an economic impact of about three times the direct healthcare expenditures or about 1 percent of Gross Domestic Product. The growing risks of antimicrobial resistant microorganisms, especially antibiotic resistant bacteria including methicillin-resistant Staphylococcus aureus, necessitate the development of a new generation of antibiotics. Posing an additional challenge to drug design, many bacteria, including Mycobacterium tuberculosis, Salmonella, Listeria, and Brucella, also have the ability to inhabit human cells, often macrophages. Purdue University researchers have developed a broad-spectrum antibiotic that effectively enters human cells. This synthetic, proline-rich antimicrobial peptide has proven to kill a number of Gram-negative and Gram-positive bacteria including MRSA. This peptide effectively invades macrophages and exhibits strong intracellular activity while causing no damage to red blood cells as compared to most antimicrobial peptides. This effective peptide antibiotic shows promise as a candidate in the fight against antibiotic resistant bacteria. Advantages: -Effective against antimicrobial resistant bacteria including, MRSA -Does not damage red blood cells -Enters human macrophages Potential Applications: -Medical/Health -Pharmaceutical industry -Drug development for antibiotic-resistant bacteria |
|
|
|
|
May 1, 2015
Utility Patent
United States
9,533,975
Jan 3, 2017
May 1, 2014
Provisional-Patent
United States
(None)
(None)
(None)
CIP-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
